Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Novartis says it is subject of Swiss competition probe

Published 09/15/2022, 01:44 AM
Updated 09/15/2022, 01:45 AM
© Reuters. FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017.   REUTERS/Arnd Wiegmann/File Photo

BERLIN (Reuters) - Novartis is the subject of an investigation by the Swiss competition commission into patent use, the Swiss pharmaceutical company said on Thursday.

© Reuters. FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017.   REUTERS/Arnd Wiegmann/File Photo

"Novartis is fully cooperating with authorities and is confident to clarify legitimacy of its position," it said in a statement, adding that the opening of an investigation did not imply any wrongdoing or financial impact.

Novartis will not comment further on the investigation at this time, it added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.